Aldeyra Therapeutics, INC 10-Q quarterly reports

Aldeyra Therapeutics reported a reduced net loss for the quarter ended June 30, 2026, driven by lower research and development expenses, but also disclosed a new Complete Response Letter from the FDA regarding its reproxalap New Drug Application.

Aldeyra Therapeutics announced its first quarter 2026 financial results, detailing a significant decrease in operating expenses and a net loss of $3.5 million.

Aldeyra Therapeutics reports a reduced net loss for Q3 2025, maintaining a stable cash position while its lead drug, reproxalap, awaits a critical FDA decision.

Aldeyra Therapeutics reports reduced net losses but faces continued regulatory hurdles for its lead dry eye drug, reproxalap, with a key partnership option unexercised.

Aldeyra Therapeutics reports a net loss for Q1 2025 and provides updates on its reproxalap NDA and other clinical programs.

Aldeyra Therapeutics' third quarter 2024 report reveals a net loss of $15.1 million, alongside updates on clinical programs and financial activities.

Aldeyra Therapeutics' second quarter 2024 report details a net loss of $24.9 million and a decrease in cash reserves, while highlighting ongoing clinical development and strategic agreements.

Aldeyra Therapeutics reports a net loss of $8.1 million for the first quarter of 2024, with a decrease in research and development expenses compared to the same period last year.